{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:48Z","timestamp":1792271988299,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T00:00:00Z","timestamp":1276646400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10072-010-0345-y","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T16:52:20Z","timestamp":1276620740000},"page":"289-293","source":"Crossref","is-referenced-by-count":53,"title":["Swedish natalizumab (Tysabri) multiple sclerosis surveillance study"],"prefix":"10.1007","volume":"31","author":[{"given":"Fredrik","family":"Piehl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Holm\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hillert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"345_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock TA et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b14\u03b21 integrin. Nature 356:63\u201366","journal-title":"Nature"},{"key":"345_CR2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"345_CR3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911\u2013923","journal-title":"N Engl J Med"},{"key":"345_CR4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","volume":"361","author":"H Lind\u00e5","year":"2009","unstructured":"Lind\u00e5 H et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081\u20131087","journal-title":"N Engl J Med"},{"key":"345_CR5","unstructured":"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm199872.htm"},{"issue":"7","key":"345_CR6","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","volume":"64","author":"RH Roxburgh","year":"2005","unstructured":"Roxburgh RH et al (2005) Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 64(7):1144\u20131151","journal-title":"Neurology"},{"issue":"11","key":"345_CR7","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/jnnp.2005.064584","volume":"76","author":"JC Hobart","year":"2005","unstructured":"Hobart JC et al (2005) How responsive is the multiple sclerosis impact scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry 76(11):1539\u20131543","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"345_CR8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jnnp.73.6.701","volume":"73","author":"A Riazi","year":"2002","unstructured":"Riazi A et al (2002) Multiple sclerosis impact scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry 73(6):701\u2013704","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"345_CR9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1177\/1352458508090923","volume":"14","author":"RH Benedict","year":"2008","unstructured":"Benedict RH et al (2008) Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 14(7):940\u2013946","journal-title":"Mult Scler"},{"issue":"1","key":"345_CR10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/1352458506070750","volume":"13","author":"BA Parmenter","year":"2007","unstructured":"Parmenter BA et al (2007) Screening for cognitive impairment in multiple sclerosis using the symbol digit modalities test. Mult Scler 13(1):52\u201357","journal-title":"Mult Scler"},{"issue":"Suppl 2","key":"345_CR11","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1007\/s10072-008-0948-8","volume":"29","author":"GL Mancardi","year":"2008","unstructured":"Mancardi GL et al (2008) Natalizumab: a country-based surveillance program. Neurol Sci 29(Suppl 2):S235\u2013S237","journal-title":"Neurol Sci"},{"issue":"Suppl 2","key":"345_CR12","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1007\/s10072-009-0143-6","volume":"30","author":"G Tedeschi","year":"2009","unstructured":"Tedeschi G et al (2009) The pharmacovigilance program on natalizumab in Italy: 2\u00a0years of experience. Neurol Sci 30(Suppl 2):S163\u2013S165","journal-title":"Neurol Sci"},{"issue":"3","key":"345_CR13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","volume":"16","author":"AB Oturai","year":"2009","unstructured":"Oturai AB et al (2009) Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 16(3):420\u2013423","journal-title":"Eur J Neurol"},{"issue":"3","key":"345_CR14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1468-1331.2008.02519.x","volume":"16","author":"N Putzki","year":"2009","unstructured":"Putzki N et al (2009) Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol 16(3):424\u2013426","journal-title":"Eur J Neurol"},{"issue":"2","key":"345_CR15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00415-009-5294-0","volume":"257","author":"O Outteryck","year":"2010","unstructured":"Outteryck O et al (2010) Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 257(2):207\u2013211","journal-title":"J Neurol"},{"issue":"9","key":"345_CR16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","volume":"72","author":"AD Goodman","year":"2009","unstructured":"Goodman AD et al (2009) GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 72(9):806\u2013812","journal-title":"Neurology"},{"issue":"14","key":"345_CR17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"69","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69(14):1391\u20131403","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0345-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-010-0345-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-010-0345-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:11:45Z","timestamp":1559121105000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-010-0345-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":17,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1007\/s10072-010-0345-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}